SANTEN PHARMACEUTICAL (4536) FY2027 Q1 Earnings Report

Quick View

Executive Summary

Despite virtually flat revenue, the Company achieved higher revenue and earnings, driven by gross profit improvement and improved financial income and expenses. Revenue was ¥689.6B (+0.3% YoY), Operating Income was ¥81.2B (+7.2%), and Net Income was ¥72.0B (+22.8%). While the gross margin improved to 58.0%, SG&A expenses increased 10.2%, outpacing revenue growth and partially offsetting the increase in Operating Income. The fact that Net Income growth exceeded Operating Income growth was attributable to improved financial income and expenses and a lower effective tax rate.

Factors Affecting Results

【Revenue】Revenue was ¥689.6B, virtually flat at +0.3% YoY. As the Company has a single segment, it is not possible to decompose changes by business; however, top-line growth was limited, and the increase in earnings during the quarter was primarily attributable to changes in the cost structure.

【Profit and Loss】Cost of sales decreased 8.5% YoY, improving the gross margin to 58.0% (54.0% in the same period of the prior year), while Operating Income was ¥81.2B (+7.2%). Meanwhile, SG&A expenses increased 10.2% to ¥233.8B, and the SG&A ratio reached 33.9% (virtually flat compared with 33.8% in the prior year, but showing an upward trend on a year-on-year basis), partially offsetting the benefits of gross profit improvement. Financial income of ¥9.6B exceeded financial expenses of ¥7.4B, resulting in positive financial income and expenses of ¥2.2B (a deficit of ¥1.2B in the prior year), which boosted Profit Before Tax. The effective tax rate declined to 13.6% from 21.3% in the prior year, and Net Income of ¥72.0B (+22.8%) grew faster than Operating Income. Although the Company achieved higher revenue and earnings, the contribution from revenue growth was small, and the primary drivers of higher earnings were improvements in the cost ratio and temporary factors related to financial income and expenses and the tax rate.

Segment Analysis

As the Company has a single segment, it does not disclose sales and profit information by segment.

Key Financial Indicators

【Profitability】The Operating Income margin improved to 11.8% from 11.0% in the same period of the prior year, while the Net Income margin expanded to 10.4% from 8.6% in the prior year. The gross margin improved to 58.0% from 54.0% in the prior year, with improvements in the cost structure serving as the primary driver of higher profitability.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥52.6B, representing only 0.73x Net Income of ¥72.0B, indicating that cash conversion of earnings was not sufficient. The accrual ratio itself was low, and the divergence was primarily attributable to the timing of corporate tax payments and changes in working capital.【Investment Efficiency】Annualized ROE was 9.6%, and the Equity Ratio was 72.2%. Total asset turnover was low, and ROE was supported by the high Net Income margin within an asset-intensive structure.【Financial Soundness】With an Equity Ratio of 72.2%, cash and cash equivalents of ¥782.6B, and total financial liabilities of ¥614.4B, the Company was in a net cash position. Current assets of ¥2198.5B compared with current liabilities of ¥780.8B indicate ample short-term payment capacity.

Cash Flow Analysis

Operating Cash Flow (OCF) was ¥52.6B, down -31.9% YoY, and the cash conversion ratio against Net Income of ¥72.0B was only 0.73x. Although subtotal Operating Cash Flow was ¥86.2B, corporate tax payments of ¥34.4B were a downward factor. In terms of working capital, the decrease in trade receivables generated a cash inflow of ¥88.9B, while the decrease in trade payables resulted in a cash outflow of ¥83.0B, with the two factors largely offsetting each other. Investing Cash Flow was limited to an outflow of ¥9.0B, primarily consisting of capital expenditures of ¥9.5B, substantially below depreciation and amortization of ¥47.2B, indicating a light investment burden. Free Cash Flow was ¥43.6B. Financing Cash Flow resulted in an outflow of ¥78.9B, including dividend payments of ¥60.5B and share repurchases of ¥9.6B; consequently, cash and cash equivalents decreased by ¥24.2B from the beginning of the period to ¥782.6B.

Earnings Quality

The increase in earnings during the quarter included not only the recurring factor of gross margin improvement, but also highly volatile factors, namely the improvement in financial income and expenses, which shifted from a deficit of ¥1.2B in the same period of the prior year to a surplus of ¥2.2B, and the decline in the effective tax rate from 21.3% to 13.6%. The fact that the Net Income growth rate of +22.8% substantially exceeded the Operating Income growth rate of +7.2% reflects the contribution of these non-operating factors and warrants attention. The divergence between Operating Cash Flow and Net Income (ratio of 0.73x) was not attributable to a substantial accumulation of accounting accruals; rather, it was primarily caused by working capital timing effects, such as increased corporate tax payments and a decrease in trade payables, and does not materially undermine earnings quality itself.

Earnings Forecast and Guidance

The full-year Company forecast is revenue of ¥3,110B, Operating Income of ¥495.0B (+3.6% YoY), and Net Income of ¥395.0B (+7.0%), with no revisions during the quarter. The Q1 progress rates were equivalent to 22.2% for revenue, 16.4% for Operating Income, and 18.0% for Net Income (attributable to owners of the parent), all below the 25% benchmark based on a simple quarterly allocation. Operating Income progress was particularly low, requiring earnings accumulation toward the second half of the year to achieve the full-year plan.

Shareholder Returns

Dividend payments during the quarter totaled ¥60.5B, resulting in a Payout Ratio of 84.1% against cumulative Q1 Net Income of ¥72.0B. Including share repurchases of ¥9.6B, the Total Return Ratio was 97.3%; however, this is a Q1 standalone figure and does not represent the full-year level. The full-year Payout Ratio calculated from the full-year forecast dividend of ¥42 per share and forecast Net Income of ¥395.0B is approximately 34%, which is considered to be within a sustainable range. Free Cash Flow of ¥43.6B was below dividend payments of ¥60.5B, indicating that the dividend during the quarter was funded by cash on hand and retained earnings from prior periods.

Risk Factors

1. Working capital turnover efficiency: The Company held trade receivables of ¥633.2B and inventories of ¥650.7B, while Operating Cash Flow remained at 0.73x Net Income. The turnover efficiency of trade receivables and inventories is one factor behind the sluggish growth in Operating Cash Flow.

2. Margin pressure from front-loaded expenses: While revenue increased only +0.3% YoY, SG&A expenses increased +10.2%. If revenue growth does not accelerate, there is a risk that the improvement in profit margins from gross profit improvement will be offset by higher expenses.

3. Delayed progress against the full-year plan: Q1 Operating Income progress was 16.4%, and Net Income progress was 18.0%, both below the standard quarterly progress benchmark of 25%. Dependence on earnings accumulation in the second half of the year is increasing.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

The Operating Income margin is below the industry median, while the Net Income margin exceeds the median, resulting in differing industry positioning at the operating and net income levels.

Growth and Capital Efficiency

The Revenue growth rate is substantially below the industry median, placing the Company at a relative disadvantage in terms of growth within the industry.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. The gross margin improved by an equivalent of 400bp to 58.0%, and the Operating Income margin also increased to 11.8%. The fact that improvements in the cost structure supported profitability is a structural positive factor confirmed by the earnings data.

2. The Net Income growth rate of +22.8% was supported by improvements in financial income and expenses and a lower effective tax rate. The difference from Operating Income growth of +7.2% reflects the contribution of these volatile factors.

3. The two points of an Operating Cash Flow/Net Income ratio of 0.73x and Q1 earnings progress of 16.4–18.0% should be monitored with respect to the speed of earnings cash conversion and the pace of achieving the full-year plan.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,048–¥1,111 at ±1% for the cost of equity, and ¥1,075–¥1,084 at ±0.1 for ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing gap relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type model with an explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated values based solely on publicly disclosed data; these do not constitute forecasts of market prices or recommendations of specific investment actions and do not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional as necessary.

---End of Report---